AstraZeneca

Bristol Myers Squibb and AstraZeneca have quickly resolved patent infringement lawsuits around their blockbuster cancer immunotherapies. | Bristol Myers Squibb and AstraZeneca have quickly resolved patent infringement lawsuits around their blockbuster PD-1/L1 and CTLA-4 cancer immunotherapies.

By Esra Erkomay – Oncology Lead, Middle East and Africa, AstraZeneca (https://www.AstraZeneca.com) Lung cancer, once rare, is now the highest cause of mortality of cancer worldwide. Responsible for more fatalities than breast, colon, and prostate cancers combined. [1]  It claims a life every 18 seconds. In recent years, wealthier countries have recently experienced a significant…

Nearly a decade after its founding, healthcare marketing agency Nimble Works is launching a new sister shop to serve clients that it sees at the “intersection of clinical and technological innovati | Nearly a decade after its founding, healthcare marketing agency Nimble Works is launching a new sister shop to serve clients that it sees…

Big pharmaceutical companies are embracing the wave of artificial intelligence (AI) in drug development. Several companies, including AstraZeneca, Roche, Takeda, and GSK, have highlighted their efforts in utilizing AI across various stages of drug development, from research and development to manufacturing and commercialization. Consulting firm McKinsey & Company previously reported a significant increase in partnerships…

Big Phar­ma com­pa­nies are catch­ing the ar­ti­fi­cial in­tel­li­gence wave, ev­i­denced by a num­ber of drug­mak­ers’ com­ments in their half-year earn­ings re­ports this week. A hand­ful of com­pa­nies high­light­ed their AI ef­forts across drug de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion, in­clud­ing As­traZeneca, Roche, Take­da and GSK so far. Con­sult­ing firm McK­in­sey & Com­pa­ny re­port­ed a “rapid rise” in…

Image source: The Motley Fool. AstraZeneca Plc (AZN 4.68% ) Q2 2023 Earnings Call Jul 28, 2023 , 6:45 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central…

Is AstraZeneca planning to peel off its China business? By CEO Pascal Soriot’s response to that question, it may only a contingency plan. | Is AstraZeneca planning to peel off its China business? By CEO Pascal Soriot’s response to that question, it may only be a contingency plan.

AstraZeneca has secured the last piece to a global puzzle of licensing agreements with Ionis Pharmaceuticals for the rare heart disease drug eplontersen. | AstraZeneca has secured the last piece to a global puzzle of licensing agreements with Ionis for the rare heart disease drug eplontersen. The partners have now extended a global licensing deal for…

To Roche’s pharma chief Teresa Graham, no word better describes the company’s eye drug Vabysmo right now than “momentum.” | To Roche’s pharma chief Teresa Graham, no word better describes the company’s eye drug Vabysmo right now than “momentum.” Approved by the FDA in January 2022, Vabysmo already crossed the one-billion-dollar sales mark in the first…

Less than a year after announcing the world’s first digital biomarker for lung fibrosis, Qureight has announced a multi-year strategic research collaboration with AstraZeneca. The agreement with the biopharmaceutical giant will allow AstraZeneca to use Qureight’s proprietary platform and AI technology to conduct research across a range of complex lung diseases, leveraging imaging data analytics…

The company will utilise Qureight’s AI technology to undergo studies across a variety of complex lung diseases Qureight, a company focused on data analytics, has entered…